10150  The Azherl's Heel of mesenchymal colon cancers  Prof. Jan Paul Medema  Academic Medical Center  Center of Experimental and Molecular Medicine  Basic research  Basic Research; More Cure  Colon and Rectal Cancer  € 1,169,422.00
10275  Targeting bone marrow retention to provoke homelessness of the tumor cells as a strategy to cure Multiple Myeloma  Dr. Marcel Spaargaren  Academic Medical Center  Pathology  Credentialing  Basic Research; More Cure  Leukemia; Myeloma; Non-Hodgkin's Lymphoma  € 551,065.00
10510  Genetic properties of breast carcinomas associated with cancer-immune interactions  Prof. Marc van de Vijver  Academic Medical Center  Pathology  Credentialing  Basic Research; More Cure; Better Quality of Life  Breast Cancer  € 721,382.00
10113  Child-tailored image guided adaptive radiotherapy because children are not adults  Dr. Arjan Bel  Academic Medical Center  Radiation Oncology (Radiotherapy)  Clinical  More Cure; Better Quality of Life  Neuroblastoma; Not Site-Specific Cancer; Sarcoma (soft tissue)  € 455,015.50
10274  Evaluation of optimal intervals for colonoscopy surveillance: a randomized trial  Prof. Evellen Deleer  Academic Medical Center  Gastroenterology and Hepatology  Clinical  Liver cancer; Better Quality of Life  Colon and Rectal Cancer  € 1,142,391.50
10324  Randomized phase-II trial of obinutuzumab, obinutuzumab and venetoclax and standard or MRD guided venetoclax maintenance in first-line patients with CLL  Prof. Arnon Kater  Academic Medical Center  Clinical Haematology  Clinical  More Cure; Better Quality of Life  Leukemia  € 266,695.00
10460  Something old, something new: Repurposing already-approved metabolic drugs to target IDH1/2 mutations in cancer  Dr. Johanna Weinink  Academic Medical Center  Oncology  Clinical  More Cure; Better Quality of Life  Brain Tumor; Gastrointestinal Tract; Liver Cancer; Nervous System; Sarcoma (soft tissue)  Ape d’HuZes  € 181,137.00
10495  NUTriential Route In Esophageal resection Trial II (NUTRIENT II)  Dr. Misha Luyer  Catharina Ziekenhuis Eindhoven  Surgery  Clinical  More Cure; Better Quality of Life  Oesophageal Cancer  Ape d’HuZes  € 309,225.27
10506  New insights in the DNA damage response to anti-cancer platinum drugs  Prof. Wim Vermeulen  Erasmus University Medical Center Rotterdam  Genetics  Basic research  Basic Research; More Cure; Better Quality of Life  Not Site-Specific Cancer  € 533,637.00
10270  The role of APOBEC3B in breast cancer therapy resistance  Dr. John Martens  Erasmus University Medical Center Rotterdam  Medical Oncology  Credentialing  Basic Research; More Cure  Breast Cancer  € 570,802.50
10317  Hitting the prostate cancer cell via PSMA-targeted radiotherapy; safer and better  Prof. Marion de Jong  Erasmus University Medical Center Rotterdam  Radiology / Nuclear Medicine  Preadministration  More Cure  Prostate Cancer  € 590,896.40
10246  Adjunct dendritic cell based immunotherapy (DCBi) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma  Dr. Eva Madsen  Erasmus University Medical Center Rotterdam  Surgery  Clinical  More Cure; Better Quality of Life  Gastrointestinal Tract  € 599,996.65
10313  ReBACARE: a randomised controlled trial of adjuvant cytokine-based immunotherapy for patients with bladder cancer: a randomised controlled trial  Dr. Josot Boormans  Erasmus University Medical Center Rotterdam  Urology (Sophia)  Clinical  Less Cancer; More Cure  Bladder Cancer; Urological System  € 439,720.70
10320  Phase II study evaluating the feasibility and efficacy of predefined de-escalating and - escalating G-CHOP in elderly patients, with DLBCL  Dr. Pieternelle Lugtenburg  Erasmus University Medical Center Rotterdam  Haematology  Clinical  More Cure; Better Quality of Life; Non-Hodgkin's Lymphoma  € 1,309,000.00
10516  Adjunct hepatic arterial infusion pump chemotherapy after complete resection of colorectal liver metastases – a randomized controlled trial  Dr. Bas Groot Koerkamp  Erasmus University Medical Center Rotterdam  Surgery  Clinical  More Cure; Better Quality of Life  Colon and Rectal Cancer; Liver Cancer  € 589,494.20
10126  Exploring the impact of diverse chromosomal instability levels on tumour progression and disease remission  Dr. Nannette Jelluma  Hubrecht Institute  Hubrecht Institute (department)  Basic research  Basic Research; Less Cancer; More Cure  Not Site-Specific Cancer  € 790,792.00
10158  Quantifying clonal dynamics, metastatic potential and therapy resistance in breast cancer organoids using single-cell sequencing  Prof. Alexander van Oudenaarden  Hubrecht Institute  Hubrecht Institute (department)  Basic research  Basic Research  Breast Cancer  € 501,907.00
10168  Tumour-specific immunity in vulvar carcinoma and its impact on survival  Dr. Mariëtte van Poelgeest  Leiden University Medical Center  Gynaecology  Basic research  Basic Research  Vulva Cancer  € 602,280.00
10308  Oncogenic B-Cell Receptor Signalling in Aggressive B-Cell Lymphomas Patients  Prof. Hendrik Veenek  Leiden University Medical Center  Haematology  Basic research  Basic Research; More Cure  Hodgkin's Disease; Non-Hodgkin's Lymphoma  € 339,488.00
10174  Chemotherapy or not? Practice changing approach for the selection of patients for accurate chemotherapy treatment after colon cancer diagnosis  Dr. Wilma Mascer  Leiden University Medical Center  Surgery (Oncology)  Preadministration  More Cure; Better Quality of Life  Colon and Rectal Cancer  Ape d’HuZes  € 625,627.70
10473  18F-FDG positron emission tomography as adjunct treatment to radiofrequency ablation for early stage hepatocellular carcinoma (HORA EST HCC): a dose-finding study  Dr. Arjan Van Erkel  Leiden University Medical Center  Radiology  Clinical  Less cancer; More Cure; Better Quality of Life  Liver Cancer  € 257,367.90
10089  Standardizing T-Arining for endoscopic Resection of Large Non-Pedunculated Colorectal Polyps: Is it prime-time to change practice?  Dr. Silvia Sanduleanu  Maastricht UMC+ (Maastricht University)  GROW, School for Oncology and Developmental Biology  Clinical  Less cancer; More Cure; Better Quality of Life  Colon and Rectal Cancer  € 399,418.90
Cooperative and mutually exclusive genetic alterations in pediatric cancer

Dr. Patrick Kemmeren
Princess Maxima Center for Pediatric Oncology
Research Operations
Basic research
Basic Research
Not Site-Specific Cancer
€ 572,050.00

Identification of biomarkers by whole-genome sequencing and phosphoproteomics to predict responses to high-penecision cancer medicines in T-cell acute lymphoblastic leukemia

Dr. Jules Meijerink
Princess Maxima Center for Pediatric Oncology
Research Operations
Credentiaing
More Cure; Better Quality of Life
Leukemia
€ 655,556.00

Featinng chromosome 21: small chromosome, large consequences in acute lymphoblastic leukemia

Dr. Judith Boar
Princess Maxima Center for Pediatric Oncology
Research Operations
Credentiaing
More Cure
Leukemia
€ 593,382.50

Breaking therapy resistance in IKZF1 deleted Acute Lymphoblastic Leukemia

Dr. Frank van Leeuwen
Radboud University Medical Center
Paediatrics
Basic research
Basic Research; More Cure; Better Quality of Life
Leukemia
€ 490,879.60

Identify the patient and save the family – detecting hereditary pancreatic cancer

Prof. Iris Nagtegaal
Radboud University Medical Center
Pathology
Credentiaing
Less Cancer; More Cure
Breast Cancer; Colon and Rectal Cancer; Melanoma; Pancreatic Cancer
€ 459,300.30

Bimodal PSMF ligands for intra-operative tumor detection and photodynamic therapy of prostate cancer

Prof. Otto Boerman
Radboud University Medical Center
Radiology and Nuclear Medicine
Creation of modality
More Cure; Better Quality of Life
Prostate Cancer
€ 584,055.00

Intrapertioneal infuion of ex vivo-generated allogeneic natural killer cells in recurrent ovarian carcinoma patients: a phase I study

Dr. Harry Dolstra
Radboud University Medical Center
Laboratory Medicine
Clinical
More Cure
Ovarian Cancer
€ 987,463.20

Fluorescence image-guided surgery in patients with peritoneal carcinomatosis of colorectal origin

Dr. Marigkema
Radboud University Medical Center
Radiology and Nuclear Medicine
Clinical
More Cure
Colon and Rectal Cancer
€ 567,865.00

Impaired Spermato genesis and Testosterone Deficiency in Male Survivors of Childhood Cancer: a DOOG-LATER study

Dr. Jacqueline Loomen
Radboud University Medical Center
Hematology
Clinical
Better Quality of Life
Brain Tumor; Kidney Cancer; Leukemia; Nervous System Neuroublastoma; Non-Hodgkin's Lymphoma; Sarcoma (soft issue)
€ 438,068.20

Diagnostic accuracy of contrast enhanced diffusion weighted MRI for liver metastases of pancreatic cancer: towards adequate staging of pancreatic cancer

Dr. John J.J. Hermans
Radboud University Medical Center
Radiology and Nuclear Medicine
Clinical
Basic Research
Pancreatic Cancer
€ 692,147.95

Potentiating autologous T cell therapy by driving continuous IFNgamma production within the tumor

Dr. Moniek Wolters
Sanquin Research
Haematopoiesis
Basic research
Basic Research; More Cure
€ 627,445.00

On the mechanism by which targeting CD47-SIRPalpha interactions potentiates antibody therapy in cancer

Dr. Timo K. van den Berg
Sanquin Research
Blood Cell Research
Basic research
Not Site-Specific Cancer
€ 513,772.60

Precision Cancer Therapy: Profiling from Tumor Specific Defects and Synthetic Lethality in the DNA Damage Tolerance System

Dr. Heinz Jacobs
The Netherlands Cancer Institute
Biological Stress Response
Basic research
Basic Research; More Cure; Better Quality of Life
Not Site-Specific Cancer
€ 962,986.50

Enhancing the success of immunotherapy for metastatic breast cancer by overcoming tumor associated immunosuppressive mechanisms

Dr. Karin de Visser
The Netherlands Cancer Institute
Immunology
Basic research
Basic Research; More Cure; Better Quality of Life
Breast Cancer
€ 557,561.50

Membrane glycosphosphatidylinositols: novel players in cell differentiation and cancer biology

Dr. Anastassia Perakis
The Netherlands Cancer Institute
Biochemistry
Basic research
Basic Research
Not Site-Specific Cancer
€ 497,637.90

Increasing drug holiday impact on therapy-refractory cancers for more durable responses

Prof. Daniel Peaper
The Netherlands Cancer Institute
Molecular Oncology
Basic research
Basic Research; More Cure; Better Quality of Life
Melanoma
€ 565,911.00

Oncine, a platform for the discovery of novel amino acid vulnerabilities in aggressive cancer

Prof. Reuven Agami
The Netherlands Cancer Institute
Biological Stress Response
Basic research
Basic Research; More Cure; Better Quality of Life
Brain Tumor; Not Site-Specific Cancer
€ 621,641.00

Targeting phenotype switching as a therapy for melanoma

Prof. Daniel Peaper
The Netherlands Cancer Institute
Molecular Oncology
Basic research
Basic Research; More Cure; Better Quality of Life
Melanoma
€ 567,761.50

Development and validation of a multiparametric imaging model for pre-treatment response prediction in rectal cancer: the road towards organ-preservation

Prof. Regina Beets-Tan
The Netherlands Cancer Institute
Diagnostic Oncology
Credentiaing
Basic Research; More Cure; Better Quality of Life
Colon and Rectal Cancer; Gastrointestinal Tract
€ 472,397.60

Favorable and unfavorable effects of risk-reducing salpingo-oophorectomy (RRSO) in women at high genetic risk of ovarian cancer

Prof. Flora van Leeuwen
The Netherlands Cancer Institute
Psychosocial Research and Epidemiology
Credentiaing
Less cancer; Better Quality of Life
Breast Cancer; Ovarian Cancer
€ 791,172.10

Does physical exercise during adjuvant cardiac chemotherapy protect against cardiac injury among women with breast cancer?

Dr. Wim Groen
The Netherlands Cancer Institute
Psychosocial Research and Epidemiology
Credentiaing
Better Quality of Life
Breast Cancer
Ape d'HuZes
€ 336,720.00

Cardiotoxicity and second cancer risk after treatment of aggressive T cell Non-Hodgkin lymphoma

Mr. Michael Schaapveld
The Netherlands Cancer Institute
Psychosocial Research and Epidemiology
Credentiaing
Less cancer; Better Quality of Life
Non-Hodgkin's Lymphoma
Ape d'HuZes
€ 747,568.00

Statistical assessment of cancer risks from therapeutic radiation exposure incorporating the spatial distribution of radiation dose in the target organ

Dr. Michael Hauptmann
The Netherlands Cancer Institute
Psychosocial Research and Epidemiology
Creation of modality
Less cancer; Better Quality of Life
Brain Tumor; Breast Cancer; Hodgkin's Disease; Leukemia; Nervous System Neuroublastoma; Non-Hodgkin's Lymphoma; Sarcoma (soft issue)
Ape d'HuZes
€ 440,555.70

Liquid biopsy analyses of cell-free circulating tumor DNA as predictive and prognostic biomarker for colorectal cancer patients with metastatic disease

Dr. Remond Feinem
The Netherlands Cancer Institute
Diagnostic Oncology
Creation of modality
More Cure; Better Quality of Life
Colon and Rectal Cancer
€ 1,033,589.00

The Drug Rediscovery Protocol (DRUP trial)

Prof. Emile Voest
The Netherlands Cancer Institute
Molecular Oncology
Clinical
Better Quality of Life
Not Site-Specific Cancer
€ 1,745,061.87
10084 Biomarker discovery for prognostication and treatment selection in prostate cancer through Androgen Receptor profiling
Dr. Wilbert Zwart
The Netherlands Cancer Institute
Molecular Pathology
Clinical
More Cure; Better Quality of Life
Prostate Cancer
Ape d'Huizens
€ 655,645.00

10088 Focal escalation of the radiation dose to the tumor in prostate cancer
Prof. Ulrike van der Heide
The Netherlands Cancer Institute
Radiotherapy
Clinical
More Cure; Better Quality of Life
Prostate Cancer
Ape d'Huizens
€ 468,696.50

10094 CRADLE: Cancer tReElalent During pregnancy: from fetoal safety to maternal Efficacy
Prof. Frederic Amant
The Netherlands Cancer Institute
Medical Oncology
Clinical
More Cure; Better Quality of Life
Breast Cancer/Cervical Cancer/Hodgkin's Disease
Leukemia; Metastasis/Non-Hodgkin's Lymphoma
Ape d'Huizens
€ 600,666.00

10153 Datamanagement for UM 2015-7738: Multicenter evaluation of the "wait-and-see" policy for complete responders after chemoradiotherapy for rectal cancer
Prof. Gerard Beets
The Netherlands Cancer Institute
Surgical oncology
Clinical
Better Quality of Life
Colon and Rectal Cancer
Ape d'Huizens
€ 427,741.72

10123 The intermediate filament network in glioma invasion
Prof. Elly Ho
UMC Utrecht
Neurosciences
Basic research
Brain Research
Brain Tumor
Ape d'Huizens
€ 493,975.60

10456 The Mutant Adhesion and the Progression of Lobular Breast cancer.
Dr. Patrick Dersken
UMC Utrecht
Laboratories & Pharmacy
Basic research
Basic Research; More Cure; Better Quality of Life
Breast Cancer
Ape d'Huizens
€ 609,806.50

10471 Control of stem cell and cancer metastasis by PDK4/AKT/FOXO signaling
Prof. Bladewijn Burgering
UMC Utrecht
Biomedical Genetics
Basic research
Basic Research
Colon and Rectal Cancer; Not Site-Specific Cancer
Ape d'Huizens
€ 619,552.00

10496 FOOTPRINT: Finding Oncogenic muTational Processes in Liver Tumorigenesis
Prof. Edwin Cuppen
UMC Utrecht
Biomedical Genetics
Basic research
Basic Research
Liver Cancer
Ape d'Huizens
€ 525,790.00

10366 Inner Centromere Integrity and Chromosomal Instability (CIN) in Cancer
Prof. Susanne Lens
UMC Utrecht
Biomedical Genetics
Basic research
Basic Research; Not Site-Specific Cancer
Ape d'Huizens
€ 527,402.00

10474 Development of superior Wilms' tumor 1 specific gene modified CORD BLOOD T cells to treat refractory acute myeloid leukemia patients.
Dr. Nico van Til
UMC Utrecht
Laboratories & Pharmacy
Creation of modality
Basic Research; More Cure; Better Quality of Life
Leukemia
Ape d'Huizens
€ 533,554.00

10291 Image-guided response assessment of radioresponse chemotherapy for esophageal cancer patients
Dr. Gert Dr. Meijer
UMC Utrecht
UMC Utrecht Cancer Center
Clinical
More Cure; Better Quality of Life
Oesophagus Cancer
Ape d'Huizens
€ 623,809.50

10307 Hollmim-166 microshperes for natoonbimization in HCC patients: new generation microshperes for individuated treatment
Prof. Mamix Lam
UMC Utrecht
Imaging
Clinical
More Cure; Better Quality of Life
Liver Cancer
Ape d'Huizens
€ 492,314.40

10080 Oncogenic functions of the transcription factor C/EBPβ in breast cancer
Prof. Cor Calkhoven
University Medical Center Groningen
Ageing Biology
Basic research
Basic Research; Less Cancer
Breast Cancer
Ape d'Huizens
€ 660,446.00

10330 To enhance the efficacy of cancer immunotherapy by metabolic reprogramming tumour-associated immune suppressor cells
Prof. Toos Dasmen
University Medical Center Groningen
Medical Microbiology
Credentialed
More Cure
Cervical Cancer;Ovarian Cancer
Ape d'Huizens
€ 500,771.00

10477 Understanding why cancer patients experiencing depressive symptoms report no need for care
Dr. Maya Schroeners
University Medical Center Groningen
Health Sciences
Credentialed
Better Quality of Life
Not Site-Specific Cancer
Ape d'Huizens
€ 340,425.80

10504 Non-invasive whole body imaging of immune checkpoints using radionuclide small molecules as predictive biomarker for response to therapy
Prof. Hans Nijman
University Medical Center Groningen
Obstetrics and Gynaecology
Creation of modality
More Cure
Not Site-Specific Cancer
Ape d'Huizens
€ 839,863.00

10034 POINTOS: Towards patient-tailored cancer immunotherapy supported by a multifaceted predictive signature composed of integrative omics and molecular imaging
Prof. Elisabeta de Vries
University Medical Center Groningen
Medical Oncology
Clinical
More Cure
Lung Cancer;Melanoma
Ape d'Huizens
€ 1,988,916.70

15432 HOVON 138 / APODD
Prof. Edo Vellenga
University Medical Center Groningen
Hematology
Clinical
More Cure; Better Quality of Life
Leukemia
Ape d'Huizens
€ 48,596.00

10212 INTERROGATING THE PHAGOSOPHOTEOME FOR TARGETS AND MARKERS IN PANCREATIC CANCER
Dr. Connie Jimenez
VU University Medical Centre
Medical Oncology (VUmc CCA)
Basic research
Basic Research; More Cure; Better Quality of Life
Pancreatic Cancer
Ape d'Huizens
€ 835,908.75

10449 Hijacking viral strategies to induce anti-pancreatic cancer immune responses: in vivo targeting of virus-like liposomes to CD169+ antigen presenting cells.
Dr. Joko den Haan
VU University Medical Centre
Molecular Cell Biology and Immunology (VUmc CCA)
Basic research
Basic Research; More Cure; Better Quality of Life
Pancreatic Cancer
Ape d'Huizens
€ 460,831.00

10401 Evaluation of tumor-educated platelet profiles for screening and follow-up of pancreatic cancer
Dr. Elisa Giovannetti
VU University Medical Centre
Medical Oncology (VUmc CCA)
Credentialed
Less cancer; More Cure
Pancreatic Cancer
Ape d'Huizens
€ 353,467.00

10476 Epi-transcriptomic small RNA modifications as predictive signatures for therapy response in Diffuse Large B cell Lymphoma
Dr. Daniela Koppers-Lalic
VU University Medical Centre
Neurosurgery (VUmc CCA)
Credentialed
Basic Research; More Cure; Better Quality of Life
Non-Hodgkin's Lymphoma
Ape d'Huizens
€ 547,890.00

10390 Cancer risk assessment in women with vulvar intraepithelial neoplasia
Dr. Maaike Bleeker
VU University Medical Centre
Pathology (VUmc CCA)
Preclinical
Less cancer; More Cure; Better Quality of Life
Vulva Cancer
Ape d'Huizens
€ 461,982.00

10328 Phase III study comparing P-CODDX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma
Dr. Martine Chamieau
VU University Medical Centre
Hematology (VUmc CCA)
Clinical
More Cure; Better Quality of Life
Non-Hodgkin's Lymphoma
Ape d'Huizens
€ 713,954.00

Total funding Research Projects (71 projects): € 43.801.332.61
<table>
<thead>
<tr>
<th>Project Number</th>
<th>Project Title</th>
<th>Project Leader</th>
<th>Institute</th>
<th>Department</th>
<th>Research Phase</th>
<th>Mission Goal(s)</th>
<th>Tumor type</th>
<th>Assigned Funder</th>
<th>Approved budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>10140</td>
<td>Identification of tumor-initiating cells in liver cancer and their interactions with hepatitis viruses</td>
<td>Dr. Ouwee Pan</td>
<td>Erasmus University Medical Center Rotterdam</td>
<td>Gastroenterology and Hepatology</td>
<td>Basic research</td>
<td>Basic Research; Less Cancer; More Cure</td>
<td>Liver Cancer</td>
<td>Alpe d'HuZes</td>
<td>€ 549,604.40</td>
</tr>
<tr>
<td>10321</td>
<td>Role of GATA2-controlled programs in the genetic predisposition to acute leukemia</td>
<td>Dr. Emma de Pater</td>
<td>Erasmus University Medical Center Rotterdam</td>
<td>Hematology</td>
<td>Basic research</td>
<td>Basic Research; Less Cancer; More Cure; Better Quality of Life</td>
<td>Leukemia</td>
<td>Alpe d'HuZes</td>
<td>€ 517,629.50</td>
</tr>
<tr>
<td>10418</td>
<td>Resolving the POLE paradox in endometrial cancer: &quot;to treat or not to treat - that is the question&quot;</td>
<td>Dr. Tjalling Bosse</td>
<td>Leiden University Medical Center</td>
<td>Pathology</td>
<td>Credentialing</td>
<td>Basic Research; Better Quality of Life</td>
<td>Endometrial Cancer</td>
<td>Alpe d'HuZes</td>
<td>€ 506,459.50</td>
</tr>
<tr>
<td>10392</td>
<td>Decreasing the burden of knowledge by improving communication with seriously II breast cancer patients</td>
<td>Dr. Liesbeth van Vliet</td>
<td>NIVEL</td>
<td>Communication</td>
<td>Credentialing</td>
<td>Better Quality of Life</td>
<td>Breast Cancer</td>
<td>Alpe d'HuZes</td>
<td>€ 445,179.42</td>
</tr>
<tr>
<td>10218</td>
<td>Exploring high risk pediatric renal tumors in patient-derived kidney organoids</td>
<td>Dr. Jarno Drost</td>
<td>Princess Maxima Center for Pediatric Oncology</td>
<td>Research Operations</td>
<td>Basic research</td>
<td>Basic Research; More Cure</td>
<td>Kidney Cancer</td>
<td>Alpe d'HuZes</td>
<td>€ 517,654.20</td>
</tr>
<tr>
<td>10099</td>
<td>Towards personalized use of immune checkpoint inhibitors by imaging of the PD-1/PD-L1 pathway</td>
<td>Dr. Sandra Heskamp</td>
<td>Radboud University Medical Center</td>
<td>Radiology and Nuclear Medicine</td>
<td>Creation of modality</td>
<td>Basic Research; More Cure; Better Quality of Life</td>
<td>Not Site-Specific Cancer</td>
<td>Alpe d'HuZes</td>
<td>€ 656,250.00</td>
</tr>
<tr>
<td>10351</td>
<td>Boosting graft-versus-leukemia immunity by combining hypomethylating agents and immunotherapy in patients with acute myeloid leukemia</td>
<td>Dr. Willemijn Hobo</td>
<td>Radboud University Medical Center</td>
<td>Laboratory Medicine</td>
<td>Preclinical</td>
<td>More Cure</td>
<td>Leukemia</td>
<td>Alpe d'HuZes</td>
<td>€ 601,250.00</td>
</tr>
<tr>
<td>10267</td>
<td>Customized cord blood-derived dendritic cells to get better disease control in refractory childhood cancers</td>
<td>Dr. Maud Plantinga</td>
<td>UMC Utrecht</td>
<td>Laboratories &amp; Pharmacy</td>
<td>Creation of modality</td>
<td>Basic Research; More Cure</td>
<td>Leukemia</td>
<td>Alpe d'HuZes</td>
<td>€ 478,514.40</td>
</tr>
</tbody>
</table>

**Total funding Young Investigator Grants (8 projects):** € 4,271,538.42

**UNIQUE HIGH RISK PROJECTS**

<table>
<thead>
<tr>
<th>Project Number</th>
<th>Project Title</th>
<th>Project Leader</th>
<th>Institute</th>
<th>Department</th>
<th>Research Phase</th>
<th>Mission Goal(s)</th>
<th>Tumor type</th>
<th>Assigned Funder</th>
<th>Approved budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>10429</td>
<td>Developing a mass-spectrometry-based screening method to identify targets for immunotherapy to cure and prevent hepatitis B-related liver cancer</td>
<td>Dr. Sonja Buschow</td>
<td>Erasmus University Medical Center Rotterdam</td>
<td>Gastroenterology and Hepatology</td>
<td>Credentialing</td>
<td>Basic Research; Less Cancer; Better Quality of Life</td>
<td>Liver Cancer</td>
<td>Alpe d'HuZes</td>
<td>€ 149,437.00</td>
</tr>
<tr>
<td>10436</td>
<td>Toward removing the UN from BRCA2 variants of Unknown significance: importance of protein domains in conformational flexibility</td>
<td>Prof. Claire Wyman</td>
<td>Erasmus University Medical Center Rotterdam</td>
<td>Radiotherapy</td>
<td>Basic research</td>
<td>Basic Research; More Cure</td>
<td>Breast Cancer; Ovarian Cancer</td>
<td>Alpe d'HuZes</td>
<td>€ 149,999.90</td>
</tr>
<tr>
<td>10222</td>
<td>HLA class I restricted neoantigens as targets for immunotherapy of acute myeloid leukemia</td>
<td>Dr. Marike Griffioen</td>
<td>Leiden University Medical Center</td>
<td>Hematology</td>
<td>Basic research</td>
<td>Basic Research; More Cure; Leukemia</td>
<td>Leukemia</td>
<td>Alpe d'HuZes</td>
<td>€ 150,640.50</td>
</tr>
<tr>
<td>10339</td>
<td>Blood vessel stabilization induced by targeting pericytes in cancer therapies</td>
<td>Dr. Frans Kok</td>
<td>Leiden University Medical Center</td>
<td>Internal medicine</td>
<td>Preclinical</td>
<td>More Cure</td>
<td>Brain Tumor; Breast Cancer; Colon and Rectal Cancer</td>
<td>Alpe d'HuZes</td>
<td>€ 150,000.00</td>
</tr>
<tr>
<td>10417</td>
<td>Prediction and modification of treatment response in esophageal cancer</td>
<td>Prof. John Plukker</td>
<td>University Medical Center Groningen</td>
<td>Medical Oncology</td>
<td>Preclinical</td>
<td>More Cure; Better Quality of Life</td>
<td>Oesophagad Cancer</td>
<td>Alpe d'HuZes</td>
<td>€ 146,214.50</td>
</tr>
<tr>
<td>10478</td>
<td>Exploring the role of long non-coding RNAs in B-cell lymphoma</td>
<td>Prof. Anke van den Berg</td>
<td>University Medical Center Groningen</td>
<td>Pathology and Medical Biology</td>
<td>Basic research</td>
<td>Basic Research; Hodgkin's Disease/Non-Hodgkin's Lymphoma</td>
<td>Hodgkin's Disease/Non-Hodgkin's Lymphoma</td>
<td>Alpe d'HuZes</td>
<td>€ 149,972.50</td>
</tr>
<tr>
<td>10491</td>
<td>Evaluating genomic heterogeneity at the single cell level as a predictor of response to treatment of NBLCLC patients</td>
<td>Prof. Harry Groen</td>
<td>University Medical Center Groningen</td>
<td>Pulmonary Diseases</td>
<td>Basic research</td>
<td>Basic Research; Lung Cancer</td>
<td>Lung Cancer</td>
<td>Alpe d'HuZes</td>
<td>€ 151,361.60</td>
</tr>
<tr>
<td>10271</td>
<td>Chromosomes: Structure and clinical relevance of a newly discovered genome rearrangement phenomenon</td>
<td>Prof. Harry Groen</td>
<td>VU University Medical Centre</td>
<td>Pathology (VUmc CCA)</td>
<td>Basic research</td>
<td>Basic Research; Not Site-Specific Cancer</td>
<td>Not Site-Specific Cancer</td>
<td>Alpe d'HuZes</td>
<td>€ 182,999.90</td>
</tr>
<tr>
<td>10395</td>
<td>RNA modifying enzymes diversify the microRNA repertoire and function during early stage cancer development</td>
<td>Dr. Renske Steenbergen</td>
<td>VU University Medical Centre</td>
<td>Pathology (VUmc CCA)</td>
<td>Basic research</td>
<td>Basic Research; Less Cancer; Better Quality of Life</td>
<td>Not Site-Specific Cancer</td>
<td>Alpe d'HuZes</td>
<td>€ 158,240.00</td>
</tr>
</tbody>
</table>

**Total Funding Unique High Risk Projects (9 projects):** € 1,388,865.90

**Total funding CALL 2016-I:** € 49,461,736.93
## OVERVIEW

### Research tracks & research phases

<table>
<thead>
<tr>
<th>Research track</th>
<th>Number of projects</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exploration track</td>
<td>50</td>
<td>€ 25,918,980.57</td>
</tr>
<tr>
<td>Basic research</td>
<td>33</td>
<td>€ 17,176,015.05</td>
</tr>
<tr>
<td>Credentialing</td>
<td>17</td>
<td>€ 8,742,965.52</td>
</tr>
<tr>
<td>Development track</td>
<td>38</td>
<td>€ 23,542,756.36</td>
</tr>
<tr>
<td>Creation of modality</td>
<td>7</td>
<td>€ 4,566,377.10</td>
</tr>
<tr>
<td>Preclinical</td>
<td>6</td>
<td>€ 2,575,970.60</td>
</tr>
<tr>
<td>Clinical</td>
<td>25</td>
<td>€ 16,400,408.68</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>88</strong></td>
<td><strong>€ 49,461,736.93</strong></td>
</tr>
</tbody>
</table>

### Funding types & research phases

<table>
<thead>
<tr>
<th>Research Projects</th>
<th>Number of projects</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic research</td>
<td>24</td>
<td>€ 14,648,912.55</td>
</tr>
<tr>
<td>Credentialing</td>
<td>14</td>
<td>€ 7,641,889.62</td>
</tr>
<tr>
<td>Creation of modality</td>
<td>5</td>
<td>€ 3,431,615.70</td>
</tr>
<tr>
<td>Preclinical</td>
<td>3</td>
<td>€ 1,678,506.10</td>
</tr>
<tr>
<td>Clinical</td>
<td>25</td>
<td>€ 16,400,408.68</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>71</strong></td>
<td><strong>€ 43,801,332.61</strong></td>
</tr>
</tbody>
</table>

| Young Investigator Grants    | 8                  | € 4,271,538.42  |
| Basic research               | 3                  | € 1,583,888.12  |
| Credentialing                | 2                  | € 951,638.92    |
| Creation of modality         | 2                  | € 1,134,761.49  |
| Preclinical                  | 1                  | € 601,250.00    |
| Unique High Risk Projects    | 9                  | € 1,368,965.90  |
| Basic research               | 6                  | € 943,214.45    |
| Credentialing                | 1                  | € 149,437.00    |
| Preclinical                  | 2                  | € 296,214.55    |
| **Total**                    | **88**             | **€ 49,461,736.93** |

---

**Explanation:**

- The table under "Research tracks & research phases" lists various research tracks and the number of projects along with their funding amounts.
- Similarly, the table under "Funding types & research phases" categorizes funding types and their associated research phases, along with the number of projects and funding amounts.